Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Share-based Compensation: 2018-2024

Historic Share-based Compensation for Avidity Biosciences (RNA) over the last 7 years, with Dec 2024 value amounting to $51.4 million.

  • Avidity Biosciences' Share-based Compensation rose 35.00% to $19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.6 million, marking a year-over-year increase of 45.73%. This contributed to the annual value of $51.4 million for FY2024, which is 34.38% up from last year.
  • Per Avidity Biosciences' latest filing, its Share-based Compensation stood at $51.4 million for FY2024, which was up 34.38% from $38.2 million recorded in FY2023.
  • Avidity Biosciences' 5-year Share-based Compensation high stood at $51.4 million for FY2024, and its period low was $4.3 million during FY2020.
  • For the 3-year period, Avidity Biosciences' Share-based Compensation averaged around $38.9 million, with its median value being $38.2 million (2023).
  • Data for Avidity Biosciences' Share-based Compensation shows a peak YoY soared of 961.58% (in 2020) over the last 5 years.
  • Over the past 5 years, Avidity Biosciences' Share-based Compensation (Yearly) stood at $4.3 million in 2020, then spiked by 295.73% to $17.1 million in 2021, then spiked by 59.12% to $27.1 million in 2022, then surged by 40.84% to $38.2 million in 2023, then surged by 34.38% to $51.4 million in 2024.